Angion Biomedica Corp is a late-stage clinical company focused on developing small molecules aimed at treating acute organ injury and chronic fibrosis. The company's lead product, ANG-3777, is designed to activate the HGF c-Met pathway, a critical mechanism in organ repair. Angion's primary market includes patients suffering from acute kidney injury related to kidney transplantation and acute lung injury associated with COVID-19 pneumonia. The business model revolves around advancing its clinical trials to achieve regulatory approval, thereby enabling commercialization and partnerships with healthcare providers and pharmaceutical companies. Revenue is generated through the development and potential future sales of its therapeutic products, as well as possible licensing agreements. Angion operates in the biopharmaceutical sector, targeting unmet medical needs in organ injury and fibrosis.

Keywords: small molecules, acute organ injury, chronic fibrosis, kidney injury, lung injury, HGF c-Met pathway, clinical trials, biopharmaceutical, organ repair, therapeutic products.